Eye injection for untreated wet age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This study tests an investigational drug given as an eye injection to treat wet age-related macular degeneration (AMD) in people who have not been treated before. The goal is to see if it can help improve vision and reduce the need for frequent injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 50 years old.
- You must have wet (neovascular) age-related macular degeneration that has not been treated before.
- The disease must be active and affecting the center of your vision, with a certain level of vision loss (between 20/40 and 20/320 on an eye chart).
- You must be able to give informed consent.
- You cannot be pregnant or breastfeeding, have had recent cataract surgery, uncontrolled glaucoma or high blood pressure, or a recent stroke or heart attack.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine given as an eye injection to treat wet age-related macular degeneration (AMD), a condition that causes blurry or lost vision. The treatment aims to improve vision by targeting abnormal blood vessels in the eye.
This trial tests a new eye injection to treat wet age-related macular degeneration (AMD), a condition that can cause blurry vision. The study checks if the injection is safe and helpful for people with active AMD.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This study tests a higher dose of a drug called aflibercept, given as eye injections, for people with untreated wet age-related macular degeneration (AMD). The goal is to see if it can improve vision and how often it needs to be given.
Hear when a new Wet Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.